Topics

Clinical Trials About "Melanoma Research Foundation Welcomes Katie Couric 18th Annual" RSS

04:55 EDT 29th March 2020 | BioPortfolio

We list hundreds of Clinical Trials about "Melanoma Research Foundation Welcomes Katie Couric 18th Annual" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Melanoma Research Foundation Welcomes Katie Couric 18th Annual" on BioPortfolio

We have published hundreds of Melanoma Research Foundation Welcomes Katie Couric 18th Annual news stories on BioPortfolio along with dozens of Melanoma Research Foundation Welcomes Katie Couric 18th Annual Clinical Trials and PubMed Articles about Melanoma Research Foundation Welcomes Katie Couric 18th Annual for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Melanoma Research Foundation Welcomes Katie Couric 18th Annual Companies in our database. You can also find out about relevant Melanoma Research Foundation Welcomes Katie Couric 18th Annual Drugs and Medications on this site too.

Showing "Melanoma Research Foundation Welcomes Katie Couric 18th Annual" Clinical Trials 1–25 of 15,000+

Relevant

Teaching Skin Self -Examination to Melanoma Patients and Their Skin Check Partners

The proposed study is a continuation of a research program (STU00017005: Interventions to teach melanoma patients skin self-examination) designed to increase early detection of melanomas before they metastasize. In 2015, approximately 73,870 individuals in the U.S. will be diagnosed with invasive melanoma and about 9,940 will die from the disease. During 2002-2011, melanoma incidence increased at an average annual rate of 1.6% for men and 1.5% for women. People with a history o...


A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

Participants with advanced or metastatic mucosal melanoma (cohort A) and acral lentiginous melanoma (cohort B) eligible for treatment with nivolumab in combination with ipilimumab followed by nivolumab therapy will submit tissue blocks from tumors of malignant melanoma for histopathology review and immunohistochemistry analysis at Georgetown University-Lombardi Comprehensive Cancer Center. Pretreatment blood will be drawn and stored in the Melanoma Research Foundation Breakthro...

Natural History of Infants With Patent Processus Vaginalis

This will be a multi-center prospective observational study of all patients who undergo laparoscopic pyloromyotomy. Subjects who have PPV will be followed up to just before their 18th birthday through annual phone calls or emails to determine the incidence and timing of subsequent inguinal hernia.


Interferon Toxicities in Melanoma Treatment

The primary objective of this study is to quantify and compare the prevalence of adverse events (AEs) in patients with stage III melanoma before and after initiation of interferon (IFN) therapy in a real-world setting. A secondary objective is to quantify annual costs and resource utilization before and after IFN initiation among patients with stage III melanoma in a real-world setting.

Health Behaviors, Surveillance, Psychosocial Factors, and Family Concerns

The purpose of this study is to examine the health behaviors of melanoma survivors. We want to know about their thoughts and concerns. Melanoma is a type of skin cancer. The number of people being diagnosed with melanoma is growing. Many people who are diagnosed with melanoma are young. Little research has been done to find out how melanoma survivors feel years after they have been treated.

Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma

This is a research study to look at the ways in which a treatment called INGN241 can kill melanoma cells or help the patient's immune system kill melanoma cells.

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

The purpose of this research study is to find out whether JX-594 is safe and effective for treating surgically unresectable malignant melanoma.

How Microbes and Metabolism May Predict Melanoma Treatment Outcomes

The purpose of this research study is to examine the relationship between the microbiota (microscopic organisms) in the gut and the activity of the immune system during melanoma immunotherapy.

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

The incidence of melanoma is increasing with an estimated incidence of 59,940 cases and an annual death rate of 8110 in 2007. Although patients diagnosed with early stage disease have an excellent clinical outcome, patients diagnosed with advanced or recurrent disease, continue to have a high mortality rate, even with initial optimal surgical resection. Effective adjuvant strategies are needed to increase the time to progression and to decrease the recurrence rate. Immunotherap...

French Clinical Datbase of Melanoma Patients (RIC-Mel)

With a high incidence, low survival rates and limiter availability of effective treatment, melanoma is one of the research priorities for health authorities. Optimizing the development of both academic and private research requires the availability information on the features of patients. To meet this need, the French Multidisciplinary Melanoma Group (GMFMel) in collaboration with INCa (French National Cancer Institute), the CeNGEPS (National Centre for Healthcare Products ...

Study of Weekly LOC-paclitaxel Injection for Melanoma

The goal of this clinical research study is to find the highest tolerable dose of LOC-paclitaxel when given to patients with metastatic melanoma. The safety of this drug and if it can control the disease is also being studied.

Parallel Trial of Decitabine and Peg-Interferon in Melanoma: Phase II Portion

The goal of the first phase of this clinical research study was to find the highest tolerable dose of decitabine and peginterferon alfa-2b that can be given in combination to patients with melanoma. The first phase was completed but the study did not progress to the second phase. The goals of the second phase of this clinical research are to learn if decitabine and peginterferon alfa-2b combined can help to control melanoma, and to find out which doses are more effective...

A Phase II Study of BVD-523 in Metastatic Uveal Melanoma

This research study is studying a targeted therapy called BVD-523 as a possible treatment for advanced uveal melanoma.

Alpha-1 Foundation Research Registry

The Alpha-1 Foundation Research Registry is a confidential database made up of individuals diagnosed with severe alpha-1 antitrypsin deficiency (Alpha-1) or the carrier state.

Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System

This research is being done because melanoma in the brain is very difficult to treat because it does not respond to radiation or to chemotherapy, such as temozolomide. One of the reasons for this is that the melanoma can make chemicals that signal the brain to provide new blood vessels for the tumor. The main signal is called VEGF. Bevacizumab is an antibody that blocks VEGF. The investigators want to see if the combination of bevacizumab and temozolomide will stop the melanoma...

Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors

Over 5 million new cases of skin cancer are diagnosed in the United States each year, more than all other cancers combined. Most of these cases are caused by excess exposure to ultraviolet radiation from the sun and artificial sources such as indoor tanning. Melanoma, approximately 87,000 of the annual skin cancer cases and one of the more deadly skin cancers, is on the rise. Previous research on these individuals suggests that while some change how much time they spend in the ...

Pre Transplantation Melanoma

Melanoma incidence is increase in global population and number of transplantation also. However immunosuppressor increase recurrence risk of melanoma. There are more and more cases of eligible patients to transplant with an antecedent of melanoma. There is no guideline yet. Main objective is survival time without melanoma recurrence in this population to do guideline of time limit or not between melanoma and transplantation by stage.

A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

The purpose of this clinical research study is to evaluate the Best Overall Response Rate (BORR), (as per modified WHO criteria) in patients with previously treated melanoma-Stage III (unresectable) or Stage IV melanoma receiving 10 mg/kg of ipilimumab. The safety of this product will also be evaluated.

Sample Collection From Melanoma Patients

The goal of this laboratory research study is to collect blood and tumor samples from patients with malignant melanoma. Researchers want to store these samples in a secure and confidential laboratory at M. D. Anderson. Researchers will use the information that is learned in this study to help find ways to improve treatment for melanoma and other cancers.

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

The purpose of this research study is to determine the safety of using the study drugs bevacizumab and ipilimumab together, and the doses in combination which can be given to people safely. This study also seeks to investigate whether using both study drugs lengthens the amount of time before the participants melanoma worsens.

Maine Lung Cancer Coalition: Using CHWs for the Annual Lung Cancer Screening Reminder

This research study will test whether support from a Community Health Worker (CHW) to address barriers to annual LDCT screening will result in an increased number of patients who receive the annual screening as per the recommended standard of care compared to passive outreach using a reminder letter.

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

The purpose of this clinical study is to examine the safety, immunogenicity and clinical activity of the immunotherapeutic product GSK2302025A administered as a first line treatment in patients with unresectable and progressive metastatic cutaneous melanoma. Citations: Epping MT, Bernards R. A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res. 2006; 66: 10639-10642. Kruit WH, Suciu S, Dreno B et al. Immunization ...

Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma

This research is being done to find out the safety of MORAb-028 in subjects with metastatic melanoma.

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether combining melanoma vaccine with interleukin-2 is more effective than vaccine therapy alone in treating metastatic melanoma. PURPOSE: Phase II trial to compare the effectiveness of melanoma vaccine and interleukin-2 with that of melanoma vaccine alone in treating patients who have metastatic melanoma that has not responded to previous treatment.

Using Rapid Cycle Randomized Controlled Trials to Increase Patient Engagement in the Annual Well Visits Program

NYU Langone Health calls patients to remind them to schedule their annual well-health appointments (including annual well visit, mammograms, etc.). The proposed study will test different iterations of the call script with the goal of increasing call completion rate and the number of scheduled appointments within an appropriate timeframe.


More From BioPortfolio on "Melanoma Research Foundation Welcomes Katie Couric 18th Annual"

Quick Search